What advances have been made in immune-therapy for renal cell carcinoma?
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy.
Elena
E
Verzoni
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy.
Paolo
P
Grassi
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy.
Raffaele
R
Ratta
D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D058990:Molecular Targeted Therapy; D016896:Treatment Outcome
D000074322:Antineoplastic Agents, Immunological
immune-checkpoint inhibitors; immunotherapy; renal cell carcinoma